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Abstract
A  solitary pulmonary nodule is a  round opacity less than 30 mm in diameter surrounded by normally aerated lung 
tissue. Determination of the character of the lesion following its detection (particularly when the identification was in-
cidental) may require a  complex diagnostic process. In most cases, nodules are benign in character; however, the pro-
bability of malignancy increases significantly for part-solid lesions. The main features that describe the solitary pulmona-
ry nodule in computed tomography scans include their size, shape, density, presence of calcification and rate of growth. 
PET-CT examination provides additional information on the metabolic activity of the lesions, and MRI is helpful in assessment of 
local invasion of surrounding structures. Due to limited availability and highly specialized character, these examinations are not 
routinely used. Therefore, despite development of other imaging modalities, computed tomography remains the most important 
and crucial diagnostic tool.
Clinical risk factors such as age or smoking status are very important for evaluation of the likelihood of malignancy of a nodular 
lesion. Due to the multidisciplinary nature of data required for complex assessment of a solitary nodular lesion, management 
routines are needed in the diagnostic process such as those proposed by the Fleischner Society.
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Introduction
A solitary pulmonary nodule (SPN) is a ro-
und lesion within the aerated lung visualized in 
chest imaging studies, it is a significant clinical, 
diagnostic, and economic problem, particularly 
when the finding is incidental. Since the 1990s, 
when multislice computed tomography (CT) tech-
nique became commonly available, the problem 
of incidentally detected lesions has increased in 
importance and frequency [1]. This is mostly due 
to the fact that the technique facilitates detection 
of lesions as small as 1–2 mm. According to Eu-
ropean low-dose screening studies, the incidence 
rate of nodular lesions is 19.5% [2]. Worldwide in-
cidence is estimated at 8–51% of scans, depending 
on the type of the scan, population and technical 
capabilities of the equipment [3, 4].
Most solitary pulmonary nodules are benign 
[2, 5]; however, they may also be early- as well 
as advanced-stage malignant tumors. According 
to estimations, one in 13 males and one in 16 
females will be diagnosed with lung cancer, with 
20-30% of these patients being diagnosed on the 
basis of a single focal lesion [6].
Basic radiological characterisation of a visu-
alized nodule depends on its X-ray attenuation 
(density), outline, size, and shape. All these pa-
rameters deliver much information on the nature 
of the lesion; however, do not provide final infor-
mation of benign vs. malignant character of the 
lesion. The knowledge of the diagnostic options 
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and schemes to be followed after detection of 
solitary pulmonary nodules is crucial to everyday 
pneumology practice.
Pulmonary nodules — etiology
Solitary pulmonary nodules may be classified 
according to their etiology into the following 
groups:
1) Neoplasms
— benign (e.g. hamartoma)
— malignant
— primary (lung cancer)
— secondary (metastases)
2) Inflammatory lesions
— infectious (e.g. round pneumonia)
— non-infectious (e.g. rheumatoid nodule)
3) Other (e.g. round atelectasis)
Benign neoplastic lesions
WHO classification lists several types of 
benign neoplastic lesions occurring in the lower 
respiratory tract [7, 8]. The most common lesion 
of this type is hamartoma, a tumor of mesenchy-
mal origin representing ca. 75% of benign tumors 
[9, 10]. According to the 2015 WHO guidelines, 
hamartoma localized in the lung is classified as 
a neoplastic lesion in contrast to hamartomas fo-
und in other organs; therefore, reference to “lung 
hamartoma” is recommended to differentiate this 
entity [8]. Other types of benign tumors such as 
adenoma, lipoma, papilloma, fibroma are much 
less common.
Malignant lesions
Malignant neoplastic lesions are the most 
diverse subgroup of focal pulmonary lesions. 
Depending on the histological type, they may be 
divided into epithelial (squamous cell carcinoma, 
large-cell carcinoma, small-cell carcinoma, ade-
nosquamous carcinoma, sarcomatoid carcinoma, 
carcinoid tumor, salivary gland tumor), mesen-
chymal, lymphoproliferative and miscellaneous 
ones. In addition, metastases into lungs, parti-
cularly occurring in the course of breast cancer, 
colon cancer, or renal cancer should be included 
in the group [11, 12].
Lung cancer requires a more detailed de-
scription as it is currently the most common 
malignancy in Poland. In recent years, it has been 
diagnosed in 1.2 million new patients every year 
worldwide; new cases in Poland sum up to ca. 
16,000 of male and ca. 6,000 of female patients. 
Lung cancer is the most common cause of cancer
-related deaths among women and men. In 2010, 
a total of 22,512 deaths were recorded, including 
16,716 deaths of male patients and 6,177 deaths 
of female patients [13, 14]. The risk of lung cancer 
depends mainly on active [6] or passive exposure 
to carcinogens in tobacco smoke (ca. 90% of all 
cases) [6, 15–18] as well as on certain physical 
and chemical environmental factors and genetic 
factors [13, 11].
Lung cancer develops in large bronchi or 
peripherally The peripheral form manifested by 
a solitary nodule is typical of adenocarcinoma. 
Metastases of lung cancer are most commonly 
found in the regional lymph nodes, liver, brain, 
contralateral lung, bones, and adrenal glands. 
Lung cancer may spread locally by infiltration of 
mediastinal structures, the diaphragm, pleura, 
and chest wall [13, 15, 18].
Inflammatory lesions
This heterogeneous group includes all infec-
tious and non-infectious diseases which may ma-
nifest as SPN detected in imaging studies. Major 
infectious diseases include bacterial pneumonia 
(particularly round pneumonia, which is more 
frequent in children), lung abscess, granuloma-
tous infections — mycobacterial, fungal — and 
atypical infections.
Non-infectious focal inflammatory lesions 
develop in the course of diseases such as rheuma-
toid arthritis (rheumatoid nodules), granulomato-
sis with polyangiitis (solid or cavitating nodules) 
or sarcoidosis (conglomerates of small nodules).
Other lesions
Other lung diseases that may manifest as 
SPN include mainly round atelectasis and pulmo-
nary infarction as well as pulmonary contusion, 
mucoid impaction, pulmonary sequestration, 
vascular malformation or intrapulmonary lymph 
node.
Diagnostic imaging of nodules
Diagnostic imaging techniques include plain 
chest X-ray, ultrasonography (USG), computed 
tomography (CT), magnetic resonance (MRI), and 
positron emission tomography (PET).
SPN’s  are usually detected in plain chest 
radiograph, as it is typically first-line imaging 
of choice. Posteroanterior (PA) and lateral X-ray 
images may provide information on size, shape, 
cavitation, rate of growth, and the presence of 
calcifications. Chest x-ray has low sensitivity. 
Despite the fact that it allows for detection of 
nodules as small as 5 mm, lesions of more than 
10 mm in diameter are usually identified [19].
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One of the superiorities of CT imaging as 
contrasted with plain X-ray [19, 20] is that it fa-
cilitates detection of lesions 1–2 mm in size [21]. 
CT helps in better identification of the character 
and extent of lesion. In addition, CT makes easier 
the visualization of other thoracic structures pos-
sibly related to the detected nodule (e.g. enlarged 
mediastinal lymph nodes).
Ultrasonographic technique has limited abi-
lity of assessing solitary lesions due to the fact 
that lung aeration reduces its penetrability by 
ultrasound waves. The method, however, is useful 
in diagnosing subpleural lesions and lesions that 
infiltrate the thoracic wall.
MRI as a highly specialized and not easily 
available technique is not used in routine assess-
ment of SPN’s. However, due to its high tissue 
resolution, it is particularly useful in the assess-
ment of local lesion advancement. Of all the afo-
rementioned techniques, MRI is best capable of 
revealing the relationship and the presence of any 
infiltration of the surrounding structures (chest 
wall, mediastinum, large vessels, diaphragm). It 
is also the method of choice in the assessment of 
lung apex (Pancoast’s) tumors [22, 23].
18F-Fluorodeoxyglucose (FDG) PET imaging 
of focal lesions combined with the CT scans 
is a well-studied and established method for 
evaluating ambiguous lesions larger than 1cm. 
Due to the sensitivity of 97% and specificity of 
78% [24], PET/CT is recommended in some co-
untries as the technique for routine assessment 
of potentially surgical focal lesions [22]. An 
important limitation of the method consists in 
the false negatives in cases of adenocarcinomas, 
carcinoids, and nodules smaller than 1 cm, and 
false positives in cases of infectious and inflam-
matory lesions [24, 25].
An additional, supplemental tool that faci-
litates the assessment of the likelihood of mali-
gnancy of a nodular lesion consists of different 
mathematical and statistical models that com-
bine imaging and clinical data. In recent years, 
numerous similar models were developed, 
mainly due to the widespread use of screening 
examinations and the availability of data obta-
ined therefrom. The best known models include 
Bayesian Analysis as well as models proposed 
by the Mayo Clinic, the Fleischner Society, 
and the British Thoracic Society. Preliminary 
assessment of the probability of malignancy of 
a particular lesion, while being a potentially ef-
fective strategy for the decision-making process, 
is still approximate and requires individual 
evaluation.
Radiological characteristics of focal lesions 
visualized in CT scans
Radiological characterization of lesions sho-
uld take into consideration the classification of 
focal lesions depending on various parameters 
such as their size, morphology (shape and outli-
ne), density measured by the X-ray attenuation 
expressed in Hounsfield units H.U., as well as 
the rate of growth. These types of classifications 
are aimed mainly at identification of lesions with 
a higher probability of malignancy.
Size
According to the guidelines of the Fleischner 
Society [5], a nodular lesion as visualized in a CT 
scan is a round lesion with the diameter of < 30 
mm localized within the aerated parenchyma of 
the lung. The size of the lesion translates to the 
preliminary evaluation of the malignancy which 
increases with the size; thus, about 80% of lesions 
larger than 20 mm are malignant as compared to 
as little as 1% for lesions sized 2–5 mm. Tumors, 
or focal lesions > 30 mm in size, are to be con-
sidered malignant unless proven otherwise in 
diagnostic examinations [26–28].
Density
Nodules are classified as solid and non-so-
lid (ground-glass opacity and ground-glass with 
a solid component, i.e. part-solid). Solid lesions 
represent a wide etiological spectrum from beni-
gn lesions such as hamartoma, through invasive 
cancers, to metastatic lesions (Fig. 1).
Non-solid nodules in more than one half 
of cases are benign and correspond to focal in-
flammatory lesions of post-inflammatory scars. 
Currently, however, much attention is paid to 
non-solid lesions since when discovered in-
cidentally, they are more likely to correspond to 
malignant lesions than solid lesions of similar 
size [29–31].
Ground glass opacity nodules may corre-
spond to a wide range of lesions. Tumors smaller 
than < 5 mm may represent atypical adenomatous 
hyperplasia (AAH), while larger lesions with the 
diameter of < 30 mm may correspond to adeno-
carcinoma in situ (AIS) or minimally invasive 
adenocarcinoma (MIA). AAH and AIS are pre-
invasive lesions and the complete resection of 
AAH, AIS, and MIA nodules leads to the 5-year 
survival rate of 100%.
More than 60% of semi-solid nodules are 
malignant in character [30] and may correspond 
to invasive adenocarcinoma of the lung, particu-
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Figure 2. Schematic representation of calcifications
larly lepidic predominant adenocarcinoma (LPA) 
characterized by slow tumor growth.
Calcifications
The pattern of calcifications within a lesion 
may be indicative of its character. Complete or 
central calcification is indicative of a benign 
process, while eccentric or numerous tiny amor-
phous calcifications are suggestive of the process 
being malignant [32]. Calcifications are observed 
in about 10% of cancers; unfortunately, these may 
include large, central calcifications (Fig. 2) [32].
Morphology
The assessment of the morphology of a SPN 
includes its shape (round, oval, spicular, poly-
cyclic, triangular), outline (smooth, blurred, the 
presence of ground-glass halo-sign around the 
lesion) and the presence of cavitation (Fig. 3).
The irregular, spicular shape is associated 
with the highest likelihood of the malignant cha-
racter of the lesion. Round lesions with smooth 
margin are on the other end of the malignancy 
spectrum [33]. Triangular lesions in subpleural 
and perifissural locations usually correspond to 
normal, intrapulmonary lymph nodes [32]. Solid 
lesion surrounded by a halo ground glass-opacity 
is usually observed in the course of inflammatory 
disorders, commonly in angioinvasive aspergillo-
sis; however, such findings may also be observed 
for metastases of melanoma or for adjacent pulmo-
nary parenchyma being infiltrated by the primary 
lung tumor [34].
Cavitation is observed in benign lesions, ma-
inly inflammatory (tuberculosis, fungal infection, 
granulomatosis with polyangiitis) but also in 
malignant lesions. Malignant vs. benign character 
of the lesion is indicated by the wall thickness — 
walls up to 4 mm are in 92% indicative of benign 
lesion, while walls thicker than 15 mm are in 95% 
suggestive of malignancy [35].
Growth rate
The growth rate is determined from the 
time in which the lesion volume is doubled or 
its diameter is increased by ca. 25% (which also 
corresponds to the doubling of the volume).
According to general consensus, doubling of 
the volume of a focal lesion within less than one 
month or more than 18 months is indicative of 
a benign character of the process (either inflam-
matory or neoplastic). Solid lesions stable for 2 
years are also considered benign (with volume 
doubling time being taken into consideration). 
However, one should keep in mind that this rule 
does not apply to non-solid lesions, which grow 
much slower with doubling time as long as 4 years 
[35]. An additional difficulty associated with the-
Figure 1. CT scans of solid (A), part-solid (B) and ground glass-type lesions (C)
A B C
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Figure 3. CT images of lesions of various morphology: smooth solid (A), spicular (B), cavitated (C), polycyclic (D)
A B
C D
se lesions is due to the problems with accurate 
and repeatable measurements of the solid and the 
ground glass opacity parts; therefore, computer 
assisted diagnosis (CAD) are used more and more 
commonly to achieve this end [36].
Contrast enhancement
The assessment of a  solitary pulmonary 
nodule following administration of a contrast 
agent may provide additional information on the 
nature of the lesion since contrast enhancement 
is directly related to the lesions’ vasculature 
and good vasculature is usually characteristic 
of malignant lesions [37, 38]. Full evaluation of 
the degree of enhancement requires a series of 
scans at intervals of several minutes. Nodular 
enhancement of less than 15 H.U. is suggestive 
of a benign lesion (false negatives include no-
des with central necrosis and adenocarcinoma 
[37], while the enhancement of 20–60 H.U. is 
indicative of a malignant lesion [39]. Currently, 
dynamic studies are recommended to obtain 
information about the character of lesion en-
hancement. These studies allow for continuous 
assessment of the degree of contrast enhance-
ment and the contrast washout rate [38]. Infor-
mation similar to that available from dynamic 
studies may be obtained for a  single scan by 
means of dual-energy imaging with contrast 
enhancement [40].
Unfortunately, no enhancement is pathogno-
monic for a particular benign or malignant lesion.
Diagnostic management guidelines
Numerous guidelines for the diagnostic ma-
nagement of nodular pulmonary lesions were 
developed in recent years in Europe and in the 
world. In Europe, the most common guidelines 
were proposed by the Fleischner Society. The 
most recent edition of the guidelines was proposed 
in March 2017 introducing a number of changes 
compared to the previous editions from 2005 and 
2013 [41]. The guidelines are presented in Table 1.
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Size < 6 mm Size 6–8 mm Size > 8 mm Comments
Single
Low risk No routine 
follow-up
CT at 6–12 mon-
ths, then consider 
CT at  
18–24 months
Consider CT at 3 
months, PET/CT, or 
tissue sampling
Nodules, 6 mm do not require routine follow-up,
but certain patients at high risk with suspicious
nodule morphology, upper lobe location,
or both may warrant 12-month follow-up
High risk Optional CT at 
12 months
CT at 6–12 mon-
ths, then CT
at 18–24 months
Consider CT at 3 
months, PET/CT,  
or tissue sampling
Nodules, 6 mm do not require routine follow-up, but certain 
patients at high risk with suspicious nodule morphology, upper 
lobe location, or both may warrant 12-month follow-up
Multiple
Low risk No routine 
follow-up
CT at 3–6 mon-
ths, then consider 
CT at  
18–24 months
CT at 3–6 months, 
then consider CT  
at 18–24 months
Use most suspicious nodule as guide to management. Follow
-up intervals may vary according to size and risk
High risk Optional CT at 
12 months
CT at 3–6 mon-
ths, then  
at 18–24 months
CT at 3–6 months, 
then at 18–24 
months
Use most suspicious nodule as guide to management. Follow








No routine  
follow-up
CT at 6–12 months to confirm per-
sistence, then CT every 2 years for 
5 years
In certain suspicious nodules, 6 mm, consider follow-up at 2 and  
4 years. If solid component(s) or growth develops, consider resection
Part solid No routine  
follow-up
CT at 3–6 months to confirm per-
sistence. If unchanged and solid com-
ponent remains, 6 mm, annual CT 
should be performed for 5 years
In practice, part-solid nodules cannot be defined as such until  
6 mm, and nodules, 6 mm do not usually require follow-up.  
Persistent part-solid nodules with solid components 6 mm should 
be considered highly suspicious
Multiple CT at 3–6  
months. If sta-
ble, consider CT 
at 2 and  
4 years.
CT at 3–6 months. Subsequent  
management based on the most  
suspicious nodule(s)
Multiple, 6 mm pure ground-glass nodules are usually benign, but 
consider follow-up in selected patients at high risk at 2 and 4 years
Summary
Detection of a solitary pulmonary nodule is 
associated with a significant diagnostic dilem-
ma. The radiological image of the lesion and 
its features including size, radiological density, 
shape and growth rate are insufficient for the 
final evaluation of its malignancy. Information 
obtained using more advanced imaging systems 
including PET, dynamic CT scans to assess the 
degree of enhancement, or MRI scans provide 
new yet often non-definitive data. Other risk fac-
tors such as age, smoking status or concomitant 
malignant diseases are also very important for 
the assessment of the malignancy of a particular 
lesion. Due to the complexity of the diagnostic 
process, the final decision on the management 
of each particular lesion is made on the basis of 
combination of the clinical risk and the radiolo-
gical features, therefore multidisciplinary and 
individualised approach is required.
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